Payment overview · 2025
General Payments
$13.94
1 reported records · 1 companies
Healthcare provider profile · identity verified
Michael E Block, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · DELRAY BEACH, FL · NPI 1942385919
Verified facts
What the public records show
CMS Open Payments records show Michael E Block, D.O. received $13.94 in general payments during 2025 across 1 reported records.
Lilly USA, LLC accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.94 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $13.94 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 65 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
65 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 307 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 269 | 64 |
| Levothyroxine Sodium | Levothyroxine Sodium | 207 | 49 |
| Atenolol | Atenolol | 167 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 166 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 154 | 26 |
| Methylprednisolone | Methylprednisolone | 151 | 80 |
| Donepezil Hcl | Donepezil Hcl | 137 | 19 |
| Eliquis | Apixaban | 132 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 131 | 26 |
| Gabapentin | Gabapentin | 128 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 116 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 107 | 34 |
| Clonazepam | Clonazepam | 104 | 34 |
| Alprazolam | Alprazolam | 102 | 25 |
| Metformin Hcl | Metformin Hcl | 96 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 96 | 18 |
| Omeprazole | Omeprazole | 90 | 26 |
| Celecoxib | Celecoxib | 89 | 32 |
| Simvastatin | Simvastatin | 89 | 16 |
| Lisinopril | Lisinopril | 87 | 21 |
| Losartan Potassium | Losartan Potassium | 85 | 19 |
| Furosemide | Furosemide | 82 | 28 |
| Montelukast Sodium | Montelukast Sodium | 78 | 33 |
| Sertraline Hcl | Sertraline Hcl | 78 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 70 | suppressed |
| Memantine Hcl | Memantine Hcl | 68 | suppressed |
| Azithromycin | Azithromycin | 67 | 51 |
| Trazodone Hcl | Trazodone Hcl | 66 | 18 |
| Mounjaro | Tirzepatide | 65 | 11 |
| Dutasteride | Dutasteride | 63 | suppressed |
| Mirtazapine | Mirtazapine | 63 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 16 |
| Tramadol Hcl | Tramadol Hcl | 56 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 50 | suppressed |
| Carvedilol | Carvedilol | 49 | 11 |
| Famotidine | Famotidine | 46 | suppressed |
| Potassium Chloride | Potassium Chloride | 44 | 11 |
| Buspirone Hcl | Buspirone Hcl | 43 | suppressed |
| Lorazepam | Lorazepam | 43 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | 16 |
| Clonidine Hcl | Clonidine Hcl | 42 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 42 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 41 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 37 | suppressed |
| Valsartan | Valsartan | 37 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 35 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 34 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 30 | suppressed |
| Latanoprost | Latanoprost | 30 | suppressed |
| Prednisone | Prednisone | 30 | suppressed |
| Dexamethasone | Dexamethasone | 28 | 24 |
| Diazepam | Diazepam | 28 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 27 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 27 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 26 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 23 | 14 |
| Allopurinol | Allopurinol | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | 11 |
| Spironolactone | Spironolactone | 20 | suppressed |
| Clonidine | Clonidine | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Ozempic | Semaglutide | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Galantamine Er | Galantamine Hbr | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $13.94 · 1 records | Lilly USA, LLC | MOUNJARO, ZEPBOUND | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error